Cigna Corporation

CI · NYSE · USD

Analysis

Last 4 earnings calls · through Q3 FY2026

Cigna is swapping an insurance company for a specialty drug business, and it keeps raising 2026 guidance while openly accepting that 2027 is the year the pharmacy rebuild costs it earnings. How much of Cigna's 2027 EPS growth comes from the $3 billion cost program?

  • Specialty drug services, not insurance, is where profit now grows.

    Biosimilars and specialty generics, with Revlimid now about 90% penetrated, shift profit out of the pharmacy benefit business into Specialty & Care, roughly a third of company income. That is where the capital is going. Which 2028 biosimilar launches does Cigna expect to refill specialty growth?

  • Cigna is exiting insurance lines it cannot scale.

    It exits the individual exchange at the end of 2026 and has put eviCore up for review, after selling Medicare. The exit resets the 2027 earnings starting point to roughly $30 a share, so growth must now come from US employers.

  • The pharmacy rebuild costs earnings before it earns them.

    Pharmacy benefit profit fell 28% in Q1 on client renewals and Signature spending that runs through 2027. Management guides the segment down again in 2027 as rebate pools shrink; the payoff is adoption in 2028. What margin does Cigna expect from Signature once half of clients adopt it?

Bullish
  • Specialty pharmacy expansion
    The bull case rests on specialty pharmacy, where growth in complex drugs and biosimilar dispensing is becoming the largest and fastest-growing source of company profit.
  • Rebate-free PBM transition
    Management argues the rebate-free pharmacy model protects client relationships and margins, so that segment's profit stabilizes once the transition spending ends.
  • Employer market share gains
    In health benefits, disciplined pricing and gains among small and midsize employers are adding customers even while medical costs stay elevated.
Bearish
  • Pharmacy profit compression
    The bear case is that pharmacy benefit profit is shrinking faster than the transparent model can replace it, as rebate pools compress across the industry.
  • Thinner specialty drug pipeline
    Specialty growth depends on a steady flow of new biosimilar and generic launches, and management now expects a lighter pipeline to slow that business.
  • Medical cost trend
    Medical costs keep rising persistently, so the health plan must reprice every year just to hold margins, and pricing errors show up within a single policy year.
PoliticiansInstitutionsInsiders
PoliticianTransactionAmountTradedFiled
Donald Trump
Republican · Executive
Sale≥$1KAug 28Oct 8
Donald Trump
Republican · Executive
Sale≥$100KJul 20Sep 22
Donald Trump
Republican · Executive
Sale≥$1KJul 8Sep 22
Donald Trump
Republican · Executive
Sale≥$1KJun 24Aug 22
Donald Trump
Republican · Executive
Purchase≥$100KMay 18Jul 1

Congressional trading data provided by QuiverQuant

Product segmentsGeography
FY2025 · USD

How Cigna turned $275B of revenue into $9.2B of operating income.

Revenue
Evernorth$235B▲ 18.56% YoY
Cigna Healthcare$47.4B▼ 0.24% YoY
Total revenue$275B
Operating income$9.2B3.3%